YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
New Spherix Global Insights research finds rheumatologists estimate 16% of rheumatoid arthritis patients are refractory to treatment, underscoring continued demand for differentiated therapies despite an increasingly crowded market. Exton,…
(RTTNews) - Today's top biotech gainers include Entera Bio, following an oversubscribed private placement financing; Gossamer, which is progressing toward a planned Seralutinib NDA submission in September; First Tracks, which has been firi…
(RTTNews) - Today's top biotech gainers include Virax Biolabs, following its agreement with Fosun Diagnostics; Forte Biosciences, after reporting positive vitiligo data; Connect Biopharma, with a key near-term catalyst ahead; and SANUWAVE…
(RTTNews) - Today's top gainers in the biotech space include Cuprina, which recently received FDA clearance for its maggot-based wound treatment; ABIVAX, following encouraging results from an ulcerative colitis study; ProMIS, which has a k…
(RTTNews) - Thursday's top gainers include Veru, following a Novo Nordisk collaboration; Health Catalyst, following a divestment of its revenue workflow and analytics software business; Absci, ahead of clinical trial readouts; and Alvotech…
(RTTNews) - Monday's top gainers include Turn Therapeutics following its interim analysis findings from an atopic dermatitis study; Conexeu Science on progress in its B.R.E.A.S.T. bioprinting program; LIXTE Biotechnology and its strategic…
First Tracks launched April 20th with a two-year cash-runway to advance ANB033 through celiac disease and eosinophilic esophagitis Phase 1b data and plans to initiate Phase 2 trials across four indications SAN DIEGO, May 14, 2026 (GLOBE NE…
AnaptysBio, Inc. Completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business Now exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda Announced appointment…
AnaptysBio, Inc. (NASDAQ:ANAB) is one of the best performing healthcare stocks so far in 2026. Piper Sandler cut the price target on AnaptysBio, Inc. (NASDAQ:ANAB) to $93 from $95 on May 4, reaffirming an Overweight rating on the shares. T…
AnaptysBio's (ANAB) board has approved the planned spin-off of First Tracks Biotherapeutics and a re PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
* AnaptysBio (ANAB [https://seekingalpha.com/symbol/ANAB]) has approved the spin-off of First Tracks Biotherapeutics, the company said on Friday. * The new company is expected to begin regular trading on the Nasdaq on April 20, 2026, under…
AnaptysBio, Inc. Anaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026 Anaptys to manage the financial collaborations for Jemperli with GSK and imsidolimab with Vanda,…